Sodium-glucose co-transporter 2 inhibitor use was associated with significantly lower risks for diabetic retinopathy compared with the use of dipeptidyl peptidase-4 inhibitors, sulfonylureas, and pioglitazone. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may reduce the risk of severe diabetic retinopathy threatening patients’ vision.
SGLT2 Inhibitors May Offer Better Protection Against Diabetic Retinopathy empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
Sodium-glucose co-transporter 2 inhibitor use was associated with significantly lower risks for diabetic retinopathy compared with the use of dipeptidyl peptidase-4 inhibitors, sulfonylureas, and pioglitazone. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may reduce the risk of severe diabetic retinopathy threatening patients’ vision.